Sage Therapeutics — Q3 2024 Earnings Presentation
10 slides from Sage Therapeutics's earnings presentation, Oct 29, 2024
Slide 1: Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results October 29, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement • The slides presented today and the accompanying oral presentations contain forward-looking statements, which may be – We may encounter unexpected safety or tolerability issues with respect to any of our product candidates or marketed identified by the use of words such as “ma
Slide 3: Sage Therapeutics call participants
Sage Therapeutics call participants Barry Greene Chris Benecchi Laura Gault Kimi Iguchi Mike Quirk Chief Executive Officer Chief Business Officer Chief Medical Officer Chief Financial Officer Chief Scientific Officer Sage The rapeutics © 2024 3
Slide 4: Fearlessly lead the way to create a world with better brain health.
OU R VI SI ON Fearlessly lead the way to create a world with better brain health. OU R MI SS IO N Pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Sage The rapeutics © 2024 4
Slide 5: ZURZUVAE performance in PPD continued in Q3
ZURZUVAE performance in PPD continued in Q3 $22.1M 49% ~2,000 ~40% Over 90% Total revenue; $11M in increase in revenue Total demand in increase in total of commercial and collaboration revenue quarter-over-quarter shipments demand as measured Medicaid lives covered in shipments quarter- by payor pol
Slide 6: Goal to establish ZURZUVAE as the standard of care in PPD
Goal to establish ZURZUVAE as the standard of care in PPD 1 Expand HCP 2 Support repeat writing among 3 Inspire women to discuss PPD symptoms prescriber base existing prescriber base with their HCP and ask about ZURZUVAE Please refer to the U.S. Prescribing Information for ZURZUVAE (https://document
Slide 7: LIGHTWAVE Data Summary
LIGHTWAVE Data Summary The Phase 2 LIGHTWAVE Study was a 12-week, Phase 2 randomized, double-blind, placebo- controlled study to evaluate the effects of dalzanemdor in participants with mild cognitive impairment or mild dementia due to Alzheimer’s Disease. Efficacy Safety & Tolerability • No statist
Slide 8: An opportunity across our early-stage pipeline
An opportunity across our early-stage pipeline SAGE-319 GABAA Receptor PAM • Extra-synaptic GABAA receptor preferring positive allosteric modulator • Potential indications: Neurodevelopmental and motor disorders Sage The rapeutics © 2024 8
Slide 9: Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results Financial foundation with $0.6B in cash at the end of Q3 ’24 Item Q3 ’24 Q3 ’23 Product revenue, net $0.8M $2.7M License and milestone revenue - related party $0.0M $0.0M Collaboration revenue - related party $11.0M $0.0M Other Collaboration revenue $0.0M $0.0M T
Slide 10: Q&A
Q&A Sage The rapeutics © 2024 10